PageOverview.com
 

Domains targeting keyword hemophilia a treatment

Keyword hemophilia a treatment was used in the provided list of websites.

 
Number of websites/domains displayed: 5
Results found: 5
 

Similar searches:

 

Websites discovered:

Shire Hematology Support| Hematology Resources & Copay Assistance
http://pageoverview.com/website-report/hematologysupport.com
Living with hemophilia or von Willebrand disease? Explore Shire Hematology Support to learn about treatment trial programs and copay assistance.
  • Expected expiration: July 8th in 2018
  • Creation date: July 8th in 2015
  • Renew date: July 4th in 2017
Factor VIII Therapy for Hemophilia A | AFSTYLA Antihemophilic Factor (Recombinant), Single Chain
http://pageoverview.com/website-report/afstyla.com
Learn about AFSTYLA, a Factor VIII therapy that provides long-lasting bleed protection for people with hemophilia A. Also explore how to get a free 30-day trial.
  • Expected expiration: March 12th in 2019
  • Creation date: March 12th in 2015
  • Renew date: February 9th in 2017
  • Google Analytics: 7437520-74
KOVALTRY®, Antihemophilic Factor (Recombinant)
http://pageoverview.com/website-report/kovaltry-us.com
Learn about KOVALTRY®, Antihemophilic Factor (Recombinant), including uses, safety, and administration information.
  • Expected expiration: February 27th in 2018
  • Creation date: February 27th in 2014
  • Renew date: February 22nd in 2016
Hemophilia Treatment Community | Living With Hemophilia
http://pageoverview.com/website-report/hemophiliasolutions.com
Living With Hemophilia is a place to learn everything you need to know about… living with hemophilia.
  • Expected expiration: April 27th in 2019
  • Creation date: April 27th in 2012
  • Renew date: April 23rd in 2017
Hemophilia A Treatment | HEMLIBRA® (emicizumab-kxwh)
http://pageoverview.com/website-report/hemlibra.com
Learn about HEMLIBRA® (emicizumab-kxwh), a hemophilia A treatment now approved for people with hemophilia A with factor VIII inhibitors. See BOXED WARNING. What is HEMLIBRA? HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with factor VIII inhibitors. What is the most important information I should know about HEMLIBRA? HEMLIBRA increases the potential for your blood to clot. Discontinue prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis. Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent, and the dose and schedule you should use. HEMLIBRA may cause the following serious side effects when used with aPCC (FEIBA®), including: Thrombotic microangiopathy (TMA). This is a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs. Get medical help right away if you have any of the signs and symptoms of TMA during or after treatment with HEMLIBRA. Blood clots (thrombotic events). Blood clots may form in blood vessels in your arm, leg, lung or head. Get medical help right away if you have any of the signs or symptoms of blood clots during or after treatment with HEMLIBRA. If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total. How should I use Hemlibra? See the detailed “Instructions for Use” that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes. HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading. Talk to your healthcare provider about how this may affect your care. What are the other possible side effects of HEMLIBRA? The most common side effects of HEMLIBRA include: redness, tenderness, warmth, or itching at the site of injection; headache; and joint pain. These are not all of the possible side effects of HEMLIBRA. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. Please see the HEMLIBRA full Prescribing Information and Medication Guide for more important safety information including Serious Side Effects.
  • Expected expiration: June 3rd in 2019
  • Creation date: June 3rd in 2015
  • Renew date: August 31st in 2017
0.0100 // 2024-06-15 03:24:18
All Rights reserved 2018 © PageOverview.com